Table 1.
Patient and ASCT Characteristics
| BEAM | TBC | P-value | |
|---|---|---|---|
|
| |||
| N (Patients) | 79 | 57 | |
|
| |||
| Age (mean): | 55 | 55 | 0.89 |
|
| |||
| Gender (% male): | 48 | 33 | 0.87 |
|
| |||
| Disease Status (%): | |||
| PR | 23.0 (29.1) | 18.0 (31.6) | 0.67 |
| Refractory | 1.0 (1.3) | 0 (0.0) | |
| CR | 55.0 (69.6) | 39.0 (68.4) | |
|
| |||
| Steroid exposure post-ASCT: | 21 (26.6) | 35 (61.4) | < 0.001 |
|
| |||
| Pre-ASCT Lymphopenia: | 39 (49.4) | 30 (52.6) | 0.84 |
|
| |||
| Neutrophil Engraftment, days (mean): | 10.09 | 9.53 | 0.08 |
CR, complete response; PR, partial response, Pre-ALC, ALC < 0.5 K/mcL for 14 consecutive day period from 0 to day -100; Steroid exposure was defined as having received an equivalent dose of prednisone 20 mg from day 0–180.